Volume | 64,689 |
|
|||||
News | - | ||||||
Day High | 4.4892 | Low High |
|||||
Day Low | 4.18 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Inozyme Pharma Inc | INZY | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.39 | 4.18 | 4.4892 | 4.40 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
775 | 64,689 | $ 4.24 | $ 274,245 | - | 2.689 - 7.795 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:49:57 | 3 | $ 4.26 | USD |
Inozyme Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
263.77M | 61.77M | - | 0 | -71.17M | -1.15 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Inozyme Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INZY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.64 | 4.82 | 4.18 | 4.45 | 637,398 | -0.38 | -8.19% |
1 Month | 7.50 | 7.795 | 4.18 | 5.71 | 897,774 | -3.24 | -43.20% |
3 Months | 5.53 | 7.795 | 4.18 | 5.92 | 694,296 | -1.27 | -22.97% |
6 Months | 2.99 | 7.795 | 2.689 | 5.13 | 544,226 | 1.27 | 42.47% |
1 Year | 5.82 | 7.795 | 2.689 | 5.18 | 572,994 | -1.56 | -26.80% |
3 Years | 19.01 | 19.58 | 0.991 | 4.63 | 405,363 | -14.75 | -77.59% |
5 Years | 17.93 | 31.6499 | 0.991 | 5.37 | 337,671 | -13.67 | -76.24% |
Inozyme Pharma Description
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. |